12933_2017_595_MOESM3_ESM.pdf (103.91 kB)
MOESM3 of Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
journal contribution
posted on 2017-09-13, 05:00 authored by Pia Pollack, Kristina Chadwick, David Smith, Martin Billger, Boaz Hirshberg, Nayyar Iqbal, David BoultonAdditional file 3. Saxagliptin and 5-hydroxy saxagliptin pharmacokinetic parameters for multiple ascending dose study in patients with T2DM.